MedPharm, a Guildford, UK-based topical and transdermal Contract Development and Manufacturing Organization (CDMO) and Ampersand Capital Partners portfolio company, announced a merger with Tergus Pharma, a Research Triangle Park, NC-based end-to-end contract service provider and a Great Point Partners portfolio company.
The combined organization will operate under the MedPharm name, establishingĀ an end-to-end CDMO with scientific, clinical trial manufacturing and commercial production capabilities.
As part of this transaction, Tergus Pharma CEO Michael Kane has been appointed CEO of MedPharm while Patrick Walsh will continue to serve as Executive Chairman of MedPharm.
The merged business is positioned as a player in delivering a full suite of drug development and manufacturing services to innovators of all sizes focused on advancing topical and transepithelial pharmaceuticals. The strategic combination of Tergus and MedPharm’s capabilitiesĀ enables commercial production and serializationĀ to existing formulation development,Ā in vitroĀ testingĀ and clinical manufacturingĀ within one integrated organization. Expanded capabilities will also include the development and manufacture of hormone-based and highly potent drugs at the company’s GMP manufacturing facility inĀ Durham, NC.
Tergus lead investorĀ Great Point Partners willĀ retain a significant minorityĀ ownership stakeĀ in the newly combined MedPharm, while private equity firms Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership.
FinSMEs
08/07/2024